---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003512"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:52:35.010704+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# EyePoint doses first patient in Phase 2 VERONA trial of EYP-1901 for DME

## Summary
- EYP-1901 (vorolanib/Durasert E) enters Phase 2 for diabetic macular edema; ~25 patients to be enrolled.
- Primary endpoint: time to first supplemental aflibercept injection up to 24 weeks.
- Topline data from VERONA expected in Q1 2025; PAVIA NPDR data due Q2 2024.
- First Phase 3 pivotal trial in wet AMD anticipated to start in H2 2024.

## SEC filing metadata
- accession: 0000950170-24-003512
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/0000950170-24-003512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/eypt-20240110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003512
- JSON: https://secwatch.observer/filing/0000950170-24-003512.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.